Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: First results from a prospective multicenter German diagnostic study

Leukemia Research

Volumn 37, Issue 8, 2013, Pages 900-906

  Braulke, Friederike ^a   Jung, Klaus ^a   Schanz, Julie ^a   Götze, Katharina ^b   Müller Thomas, Catharina ^b   Platzbecker, Uwe ^c   Germing, Ulrich ^d   Brümmendorf, Tim H ^e   Bug, Gesine ^f   Ottmann, Oliver ^f   Giagounidis, Aristoteles A N ^g   Stadler, Michael ^h   Hofmann, Wolf Karsten ⁱ   Schafhausen, Philippe ^j   Lübbert, Michael ^k   Schlenk, Richard F ^l   Blau, Igor W ^m   Ganster, Christina ^a   Pfeiffer, Sebastian ^a   Shirneshan, Katayoon ^a   Metz, Michael ⁿ   Detken, Sven ^o   Seraphin, Jörg ^o   Jentsch Ullrich, Kathleen ^p   Böhme, Angelika ^q   Schmidt, Burkhard ^r   Trümper, Lorenz ^a   Haase, Detlef ^a   more..

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e RWTH AACHEN UNIVERSITY   (Germany)

^f GOETHE UNIVERSITY   (Germany)

^g MARIEN HOSPITAL DÜSSELDORF   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ UNIVERSITY OF MANNHEIM   (Germany)

^j UNIVERSITY OF HAMBURG   (Germany)

^k UNIVERSITY OF FREIBURG   (Germany)

^l UNIVERSITY OF ULM   (Germany)

^m CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁿ Division of Hematology/Oncology   (Germany)

^o Northeim   (Germany)

^p Gemeinschaftspraxis for Hematology and Oncology   (Germany)

^q Practice for Hematology and Oncology   (Germany)

^r Center for Hematology and Oncology   (Germany)

more..

Author keywords

CD34+; Chromosomal aberrations; Cytogenetics; FISH; Karyotype evolution; MDS

Indexed keywords

AZACITIDINE; LENALIDOMIDE;

ADULT; AGED; ARTICLE; CD34+ PERIPHERAL BLOOD CELL; CHROMOSOME ANALYSIS; CHROMOSOME BAND; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC SCREENING; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SEPARATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NON INVASIVE MEASUREMENT; PATIENT MONITORING; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RELIABILITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CHROMOSOME ABERRATIONS; CHROMOSOME BANDING; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879788390     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.03.019     Document Type: Article

References (25)

1. Silverman L.R. Neoplasms of the hematopoietic system: myelodysplastic syndrome. Cancer medicine 2000, 1931-1946. Hamilton, Canada, BC Decker. J. Holland, E.I. Frei, R.J. Bast (Eds.).
2. Fenaux P. Myelodysplastic syndromes: from pathogenesis and prognosis to treatment. Semin Hematol 2004, 41:6-12.
3. Germing U., Gattermann N., Strupp C., Aivado M., Aul C. Validation of WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000, 24:983-992.
4. Solé F., Espinet B., Sanz G.F., Cervera J., Calasanz M.J., Luño E., et al. Incidence, characterisation and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol 2000, 108:346-356.
5. List A., Kurtin S., Roe D.J., Buresh A., Mahadevan D., Fuchs D., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352:549-557.
6. Haase D., Germing U., Schanz J., Pfeilstöcker M., Nösslinger T., Hildebrandt B., et al. New insights into prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110:4385-4395.
7. Haase D., Fonatsch C., Freund M., Wörmann B., Bodenstein H., Bartels H., et al. Cytogenetic findings in 179 patients with myelodysplastic syndromes. Ann Hematol 1995, 70:171-187.
8. Bernasconi P., Klersy C., Boni M., Cavigliano P.M., Calatroni S., Giardini I., et al. Incidence and prognostic significance of karyotype abnormalities in de novo myelodysplastic syndromes: a study on 331 patients from a single institution. Leukemia 2005, 19:1424-1431.
9. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplstic syndromes. Blood 1997, 89:2079-2088.
10. Giagounidis A.A.N., Germing U., Strupp C., Hildebrandt B., Heinsch M., Aul C. Prognosis of patients with del(5q) MDS and complex aberrant karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol 2005, 84:569-571.
11. Rigolin G.M., Bigoni R., Milani R., Cavazzini F., Roberti M.G., Bardi A., et al. Clinical imprtance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. Leukemia 2001, 15:1841-1847.
12. Haase D., Feuring-Buske M., Könemann S., Fonatsch C., Troff C., Verbeek W., et al. Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations. Blood 1995, 86:2906-2912.
13. Vehmeyer K., Haase D., Alves F. Increased peripheral stem cell pool in MDS: an indication of disease progression?. Leuk Res 2001, 25:955-959.
14. Braulke F., Schanz J., Jung K., Shirneshan K., Schulte K., Schuetze C., et al. FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients. Leuk Res 2010, 34:1296-1301.
15. Shaffer LG, Slovak ML, Campbell LJ (Eds). An international system for human cytogenetic nomenclature. Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. S. Karger A.G: Basel, 2009.
16. Ganster C., Braulke F., Shirneshan K., Kämpfe D., Platzbecker U., Söling U., et al. Proof of Y-loss as clonal abnormality in MDS by comparative analysis of CD34+ and CD3+ peripheral blood cells [abstract]. Blood 2011, 118. abstract 3800.
17. Costa D., Valera S., Carrió A., Arias A., Muñoz C., Rozman M., et al. Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do?. Leuk Res 2010, 34:1437-1441.
18. Jiang H., Xue Y., Wand Q., Pan J., Wu Y., Zhang J., et al. The utility of fluorescence in situ hybridization analysis in diagnosing myelodysplastic syndromes is limited to cases with karyotype failure. Leuk Res 2012, 36:448-452.
19. Pitchford C.W., Hettinga A.C., Reichard K.K. Fluorescence in situ hybridization testing for -5/5q-, -7/7q-, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study. Am J Clin Pathol 2010, 133:260-264.
20. Kwon W.K., Lee J.Y., Mun Y.C., Seong C.M., Chung W.S., Huh J. Clinical utility of FISH analysis in adition to G-banded karyotype in hematologic malignancies and proposal of practical research. Korean J Hematol 2010, 45:171-176.
21. McDevitt M.A., Condon M., Stamberg J., Karp J.E., McDiarmid M. Fluorescent in situ hybridization (FISH) in bone marrow and peripheral blood of leukemia patients: implications for occupational surveillance. Mutat Res 2007, 629:24-31.
22. Pinheiro R.F., Chauffaille M.L.L.F. Comparison of I-FISH and G-banding for the detection of chromosomal abnormalities during the evolution of myelodysplastic syndrome. Braz J Med Biol Res 2009, 42:1110-1112.
23. Cherry A.M., Slovak M.L., Campbell L.J., Chun K., Eclache V., Haase D., et al. Will a peripheral blod (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?. Leuk Res 2012, 36:832-840.
24. Cesana C., Klersy C., Brando B., Nosari A., Scarpati B., Scampini L., et al. Prognostic value of circulating CD34+ cells in myelodysplastic syndromes. Leuk Res 2008, 32:1715-1723.
25. Schanz J., Steidl C., Fonatsch C., Pfeilstöcker M., Nösslinger T., Tuechler H., et al. Coalesced multicentric analysis of 2351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 2011, 29:1963-1970.